Inventiva (NASDAQ:IVA) Price Target Cut to $13.00

Inventiva (NASDAQ:IVA) had its target price reduced by analysts at HC Wainwright from $14.00 to $13.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 437.19% from the stock’s current price.

Separately, Stifel Nicolaus decreased their price target on Inventiva from $25.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, September 26th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Inventiva currently has a consensus rating of “Buy” and a consensus target price of $16.25.

Inventiva Trading Down 6.9 %

NASDAQ:IVA opened at $2.42 on Tuesday. The business’s fifty day moving average is $2.16 and its 200 day moving average is $2.79. Inventiva has a 52-week low of $1.53 and a 52-week high of $4.75.

Institutional Trading of Inventiva

An institutional investor recently bought a new position in Inventiva stock. Virtu Financial LLC bought a new stake in Inventiva S.A. (NASDAQ:IVA) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,490 shares of the company’s stock, valued at approximately $38,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.